00:59 , Aug 4, 2018 |  BioCentury  |  Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
17:37 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Ascletis' NDA for second HCV therapy accepted in China, company begins trading in Hong Kong

Ascletis Pharma Inc. (HKSE:1672) said China's State Drug Administration accepted its NDA for HCV therapy ravidasvir, a second-generation HCV NS5A protein inhibitor. In June, Ascletis launched HCV drug Ganovo danoprevir in China. Ascletis has rights to...
17:36 , Aug 3, 2018 |  BC Extra  |  Financial News

Ascletis ends first trading week on downturn

Ascletis Pharma Inc. (HKSE:1672) sank HK$1.84 (16%) to HK$10.02 on Friday, ending its first week of trading down 28% from its IPO price of HK$14. This week, Ascletis became the first biotech to go public on...
15:12 , Aug 1, 2018 |  BC Extra  |  Financial News

Ascletis trades flat in Hong Kong debut

Ascletis Pharma Inc. (HKSE:1672) shares ended the day unchanged at HK$14 in the company's first day of trading Wednesday. The antiviral company raised HK$3.1 billion ($400 million) in its IPO through the sale of 224.1...
21:23 , Jul 31, 2018 |  BC Extra  |  Company News

Ascletis submits Chinese NDA for second HCV therapy

Ahead of its Hong Kong trading debut Wednesday, Ascletis Pharma Inc. (HKSE:1672) said Tuesday it submitted an NDA to China's State Drug Administration for HCV therapy ravidasvir. The second-generation HCV NS5A protein inhibitor received expedited...
19:59 , Jul 27, 2018 |  BioCentury  |  Finance

First out the gate

As Ascletis Pharma Inc. (HKSE:1672) prepares for its trading debut on Aug. 1, Hong Kong Exchanges and Clearing Ltd. (HKEX) market watchers hope investor demand for biotech in the region can maintain momentum. Ascletis priced...
21:29 , Jul 20, 2018 |  BC Extra  |  Financial News

Ascletis sets terms for Hong Kong IPO

In a regulatory filing, antiviral company Ascletis Pharma Inc. (Hangzhou, China) revealed terms of its planned IPO on the Hong Kong exchange. The company hopes to raise HK$2.7-HK$3.6 billion ($342.7-$456.9 million) through the sale of...
19:28 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Gilead's Epclusa approved in China for HCV

Gilead Sciences Inc. (NASDAQ:GILD) said China's State Drug Administration (formerly China FDA) approved Epclusa sofosbuvir/velpatasvir to treat adults with chronic HCV genotypes 1-6. The agency also approved Epclusa plus ribavirin to treat adults with HCV...
16:11 , May 30, 2018 |  BC Extra  |  Company News

Gilead's Epclusa approved in China for HCV

Gilead Sciences Inc. (NASDAQ:GILD) said China's State Drug Administration (formerly China FDA) approved Epclusa sofosbuvir/velpatasvir to treat adults with chronic HCV genotypes 1-6. The agency also approved Epclusa plus ribavirin to treat adults with HCV...
18:29 , May 11, 2018 |  BC Week In Review  |  Financial News

Ascletis first to apply for HKEX biotech chapter

Ascletis Pharma Inc. (Hangzhou, China) plans to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by Morgan Stanley, Goldman Sachs and China Merchants, according to a regulatory filing on May...